Goldman Sachs analyst Corinne Johnson lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $139 from $157 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $129 from $122 at Morgan Stanley
- Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
- Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating